Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Dr. Saenger on the Need for Immunotherapy Biomarkers

August 7th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Selumetinib Combination Significantly Improves PFS but Not OS in BRAF-Positive Melanoma

August 2nd 2013

Combination treatment with selumetinib and dacarbazine significantly improved progression-free survival in patients with BRAF-positive melanoma.

T-VEC Delivers Durable Responses in Unresectable Melanoma

July 31st 2013

T-VEC manifested significant gains in durable response rate and other key clinical indicators in patients with advanced melanoma in what researchers described as the first phase III trial demonstrating the efficacy of an oncolytic virus immunotherapy.

Dr. Ribas on the Efficacy of Ipilimumab in Melanoma

July 29th 2013

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses the efficacy of ipilimumab for the treatment of melanoma.

Dr. Richard D. Carvajal on the Investigation of Selumetinib

July 25th 2013

Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, discusses the background of the investigation of selumetinib for advanced uveal melanoma.

Dr. Weber on Optimal Therapy Sequences in Melanoma

July 23rd 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, discusses sequencing immunologic and targeted therapies in patients with advanced BRAF-mutated melanoma.

Dr. Mittendorf on Peptide Vaccines for Breast Cancer

July 19th 2013

Elizabeth Mittendorf, MD, PhD, from MD Anderson Cancer Center, discusses the use of peptide vaccines for the treatment of breast cancer.

Dr. Swain Discusses Studies From the 2013 ASCO Meeting

July 15th 2013

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, highlights information presented at the 2013 American Society of Clinical Oncology (ASCO) Meeting.

Dr. Schuchter Discusses the Treatment of Melanoma

July 3rd 2013

Lynn M. Schuchter, MD, Chief, Hematology Oncology, Department of Medicine, University of Pennsylvania, discusses the treatment of advanced melanoma.

Intermittent Dosing May Overcome Resistance to Vemurafenib in Patients With Melanoma

June 24th 2013

Using an intermittent dosing strategy with vemurafenib, instead of continuous dosing, has the potential to overcome the development of resistance in patients with melanoma treated with the drug.

Dr. Weber Explores Nivolumab in Advanced Melanoma

June 21st 2013

Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center and Research Institute, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

Dr. Wolchok on Concurrent Ipilimumab and Nivolumab

June 19th 2013

Jedd D. Wolchok, MD, PhD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase I trial exploring the combination of the anti-PD-1 antibody nivolumab and ipilimumab, a CTLA-4 inhibitor, for patients with advanced melanoma.

Dr. Saenger on Combining Targeted and Immune Agents

June 12th 2013

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the idea of combining targeted and immune agents.

Dr. Andtbacka Reviews the Efficacy of T-VEC in Melanoma

June 7th 2013

Robert Andtbacka, MD, from the Huntsman Cancer Institute, provides an overview of the phase III OPTiM trial that explored treatment with talimogene laherparepvecin patients with advanced melanoma.

The Future of Melanoma Treatment

June 6th 2013

Drugs currently approved by the FDA for treatment of melanoma include aldesleukin, dabrafenib, dacarbazine, ipilimumab, trametinib, and vemurafenib. This article will explore pharmacologic agents currently being investigated for the treatment of melanoma.

Dr. Ribas on Anti-PD-1 Agent Lambrolizumab in Melanoma

June 3rd 2013

Antoni Ribas, MD, PhD, from UCLA's Jonsson Comprehensive Cancer Center, discusses preliminary results of an ongoing trial investigating the anti-PD-1 antibody lambrolizumab in patients with advanced melanoma.

GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma

June 2nd 2013

Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.

Nivolumab Delivers Enduring Benefits in Advanced Melanoma

June 2nd 2013

Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.

Dr. Sznol Describes Nivolumab in Advanced Melanoma

June 2nd 2013

Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

June 1st 2013

Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.